427,998 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Rubric Capital Management LP

Rubric Capital Management LP bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 1st quarter, Holdings Channel reports. The firm bought 427,998 shares of the company’s stock, valued at approximately $45,111,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PTGX. Vanguard Group Inc. lifted its position in shares of Protagonist Therapeutics by 27.2% during the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock valued at $472,832,000 after acquiring an additional 1,156,461 shares during the period. State Street Corp grew its holdings in shares of Protagonist Therapeutics by 18.5% in the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company’s stock worth $177,281,000 after acquiring an additional 500,924 shares during the period. Wellington Management Group LLP increased its stake in Protagonist Therapeutics by 66.2% in the 4th quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock valued at $276,992,000 after purchasing an additional 1,262,977 shares in the last quarter. UBS Group AG increased its stake in Protagonist Therapeutics by 46.1% in the 4th quarter. UBS Group AG now owns 2,770,021 shares of the company’s stock valued at $241,934,000 after purchasing an additional 874,013 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in Protagonist Therapeutics by 140.7% during the fourth quarter. Janus Henderson Group PLC now owns 2,649,981 shares of the company’s stock worth $231,355,000 after purchasing an additional 1,549,160 shares during the last quarter. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director Bryan Giraudo sold 36,000 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $100.14, for a total value of $3,605,040.00. Following the transaction, the director directly owned 27,825 shares in the company, valued at approximately $2,786,395.50. This represents a 56.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director William D. Waddill sold 9,000 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the sale, the director directly owned 7,825 shares in the company, valued at $922,880.50. This represents a 53.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 161,130 shares of company stock worth $16,355,220. Corporate insiders own 5.19% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. Johnson Rice set a $165.00 target price on Protagonist Therapeutics in a research report on Friday, July 17th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $110.00 price target on shares of Protagonist Therapeutics in a research note on Wednesday, May 6th. Wedbush boosted their price objective on shares of Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $123.00.

Protagonist Therapeutics Stock Down 0.4%

NASDAQ PTGX opened at $135.56 on Tuesday. Protagonist Therapeutics, Inc. has a fifty-two week low of $50.49 and a fifty-two week high of $143.29. The business has a fifty day moving average of $117.49 and a 200-day moving average of $101.83. The stock has a market cap of $8.72 billion, a price-to-earnings ratio of -74.90 and a beta of 1.79.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. The business had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. As a group, analysts anticipate that Protagonist Therapeutics, Inc. will post 3.69 EPS for the current year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.